FDA Accepts sNDA for Full Approval of BioMarin’s Voxzogo
BioMarin Pharmaceutical (BMRN) has received FDA acceptance of its supplemental New Drug Application seeking full approval for Voxzogo, an achondroplasia treatment. The therapy was granted accelerated approval in 2021 and is now supported by three long-term trials.
Tickers: $BMRN